Gilead and Genmab to collaborate on new HIV drug development

Gilead Sciences and Genmab have announced a new drug development collaboration that will make use of Genmab's DuoBody technology platform.

Genmab has granted Gilead one exclusive licence and an option on a second to use the DuoBody technology to create and develop bispecific antibody candidates for a therapeutic programme targeting HIV.

DuoBody facilitates the discovery of bispecific antibodies to enhance the treatment of cancer, autoimmune, infectious and central nervous system diseases. Molecules developed through this method combine the benefits of bispecificity with the strengths of conventional antibodies.

Gilead has paid Genmab an upfront fee of $5 million (3.86 million pounds), with further potential development, regulatory and sales milestones of up to $277 million to be paid depending on the progress of the first product and further milestones for subsequent products.

This deal builds on the research collaboration between Genmab and Gilead for the DuoBody technology that initially commenced in 2014.

Dr Jan van de Winkel, chief executive officer of Genmab, said: "We are pleased to add this agreement with Gilead to our growing list of commercial collaborations for our innovative DuoBody platform and we are particularly excited that the potential for DuoBody bispecific antibodies for treating HIV will be explored."

With? ?over? ?20? ?years? ?of? ?experience? ?within? ?the? ?pharmaceutical? ?market,? ?we? ?at? ?Zenopa? ?have? ?the knowledge,? ?skills? ?and? ?expertise? ?to? ?help? ?find? ?the? ?right? ?job? ?for? ?you.? ?To? ?find? ?out? ?more? ?about? ?the current? ?pharmaceutical? ?roles? ?we? ?have? ?available,? ?you? ?can? ?search? ?for? ?the? ?latest? ?job? ?roles, register? ?your? ?details,? ?or? ?contact? ?the? ?team? ?today.